AI Summary
5 min readChina has overtaken the United States as the global leader in biopharmaceutical innovation, particularly in clinical trials and novel drug approvals, due to targeted regulatory reforms since 2016. Independent researcher Cremieux Recueil explains this shift to hosts Theo Jaffey and Gabriel Dickinson, highlighting how China's streamlined processes enable faster, larger trials with lower error rates, while warning of strategic risks if the US does not adapt.
China's Rapid Rise in Trials and Approvals
For decades, the US produced about 40% of global medical innovations, but since 2016, China has surged ahead. It now runs more phase 1-3 clinical trials than the US—over 1,600 annually versus the US's similar number—after jumping from near zero two decades ago. This growth outpaces flat US and EU trends. Trials translate to approvals: China leads in first-in-class novel drugs, including gene therapies (six times more first-ever phase 1 starts in 2025 than the US), antibodies, small molecules, and frontier modalities like mRNA vaccines.
Continue reading the full summary in the app — free to try.
Read Full Summary →Free • No credit card required
What you'll learn
- 1 (00:00) **US Market Dominance in Pharma** - America represents 4% of world population but over 50% of drug sales dollars, driving innovation.
- 2 (00:40) **Shift from US to China Leadership** - US historically led in new therapies but China now surpasses in trial volume and novel drugs since 2016.
- 3 (03:58) **Guest Intro: Cremieu on Biotech Trends** - Independent researcher Cremieu (genetics, metrics, demographics) documents China's biotech surge.
- 4 (04:52) **Why Global Innovation Matters** - More innovations benefit all; China pulling weight for half world's population is positive.
- 5 (08:55) **Clinical Trial Phases Explained** - Standard ICH phases: Phase 1 safety, Phase 2 efficacy, Phase 3 large-scale confirmation, Phase 4 monitoring.
- 6 (09:49) **US Trial Volumes** - US runs 1500+ trials/year, mostly Phase 2; steady but flat trajectory.
- 7 (11:36) **China Surpasses US in Trials** - China jumped from near-zero to more trials than US post-2016 reforms; now leads EU too.
+ Full timestamped outline available in the app
Show Notes
Theo Jaffee and Gabriel Dickinson speak with Cremieux about China’s rapid rise to the top of global clinical trial output. They discuss the regulatory reforms that accelerated China’s progress, the surge in novel drug development, and what the US would need to change to stay competitive in biomedical innovation.
Resources:
Follow Cremieux on X: https://x.com/cremieuxrecueil
Follow Theo on X: https://x.com/theojaffee
Follow Gabriel on X: https://x.com/gbrl_dick
Stay Updated:
Find a16z on YouTube: YouTube
Find a16z on X
Find a16z on LinkedIn
Listen to the a16z Show on Spotify
Listen to the a16z Show on Apple Podcasts
Follow our host: https://twitter.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
More from this podcast
a16z Show →